GSA Capital Partners LLP Takes Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

GSA Capital Partners LLP acquired a new stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) in the third quarter, Holdings Channel.com reports. The fund acquired 507,694 shares of the company’s stock, valued at approximately $340,000.

A number of other institutional investors and hedge funds also recently modified their holdings of XFOR. Price T Rowe Associates Inc. MD increased its stake in shares of X4 Pharmaceuticals by 46.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after acquiring an additional 12,514 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of X4 Pharmaceuticals by 39.7% in the second quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock worth $272,000 after acquiring an additional 133,398 shares during the last quarter. Rhumbline Advisers increased its stake in shares of X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of X4 Pharmaceuticals in the second quarter worth $65,000. Finally, Ensign Peak Advisors Inc increased its stake in shares of X4 Pharmaceuticals by 4.6% in the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock worth $1,477,000 after acquiring an additional 111,032 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

Insider Buying and Selling

In other news, COO Mary Dibiase sold 67,695 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.57, for a total value of $38,586.15. Following the completion of the transaction, the chief operating officer now owns 452,060 shares in the company, valued at $257,674.20. This represents a 13.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paula Ragan sold 239,436 shares of X4 Pharmaceuticals stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the sale, the chief executive officer now directly owns 1,057,713 shares in the company, valued at $581,742.15. This represents a 18.46 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 580,800 shares of company stock valued at $321,447 over the last three months. Company insiders own 1.62% of the company’s stock.

Analyst Ratings Changes

XFOR has been the topic of several analyst reports. HC Wainwright lowered their target price on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Stifel Nicolaus reduced their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 8.3 %

Shares of NASDAQ:XFOR opened at $0.34 on Friday. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The firm has a market cap of $57.64 million, a P/E ratio of -3.76 and a beta of 0.39. X4 Pharmaceuticals, Inc. has a 12 month low of $0.26 and a 12 month high of $1.60. The company’s 50-day moving average price is $0.55 and its two-hundred day moving average price is $0.73.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.